Faes Farma (FAE) Q2 2025 earnings summary

Executive summary

• Total revenues increased by 12.3% to €307.4M, reaching the high end of guidance, with growth across all business areas.

• Pharma revenues rose 9% to €269M, led by LATAM (+17%) and Licences (+13%).

• Animal Nutrition and Health revenues surged 48% to €38.3M, driven by ISF business.

• Acquisition of Laboratorios Edol completed; contract signed for SIFI acquisition, pending financing.

• Approval of paediatric bilastine in Europe and completion of three clinical studies.

Financial highlights

• Total income reached €307.4M, up 12.3% year-over-year.

• Adjusted EBITDA was €80.5M (+2.5%), while reported EBITDA declined 6.6% due to extraordinary costs.

• Net profit was €52.2M, down 10.5% compared to H1 2024, due to extraordinary costs and M&A expenses.

• Top 3 molecules generated €127.7M (+15.6%), representing 41.5% of total revenue.

• Pharma revenues totaled €269.0M (+9%).

Outlook and guidance

• Full-year 2025 income expected to grow 8–10%.

• Adjusted EBITDA for 2025 guided to increase 3–5%, in line with H1 performance.

• Reported EBITDA for 2025 expected to decline 6–9% due to extraordinary items.

• Strategic plan targets €1B revenue and €240M EBITDA by 2030 (CAGR 11–12% and 10–11%).